Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Sebastian Schellong, MD, Henry Eriksson, MD PhD, Samuel Z. Goldhaber, MD, Martin Feuring, MD, Stefan Hantel, PhD, Jörg Kreuzer, MD, Sam Schulman, MD PhD, Ajay K Kakkar, MB, BS, PhD

Blood (2015) 126 (23): 4730.

https://doi.org/10.1182/blood.V126.23.4730.4730

Published: 2015

Journal Articles

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD PhD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 4270.

https://doi.org/10.1182/blood.V124.21.4270.4270

Published: 2014

Journal Articles

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Sam Schulman, MD PhD, Henry Eriksson, MD PhD, Ajay Kakkar, MB, BS, PhD, Clive Kearon, MB, PhD, Sebastian M Schellong, MD, Patrick Mismetti, MD, Martin Feuring, MD, Stefan Hantel, PhD, Joerg Kreuzer, MD, Samuel Z. Goldhaber, MD

Blood (2014) 124 (21): 594.

https://doi.org/10.1182/blood.V124.21.594.594

Published: 2014

Journal Articles

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Bengt I Eriksson, MD, John J Smith, MD, PhD, Joseph Caprini, MD, Stefan Hantel, PhD, Andreas Clemens, MD, Martin Feuring, MD, Gregory W Barsness, MD

Blood (2011) 118 (21): 2309.

https://doi.org/10.1182/blood.V118.21.2309.2309

Published: 2011

Journal Articles

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

Michael H Huo, MD, Andreas A Kurth, MD, Ola E Dahl, MD, Andreas Clemens, MD, Stefan Hantel, PhD, Martin Feuring, MD, Richard J Friedman, MD, Bengt I Eriksson, MD, PhD

Blood (2011) 118 (21): 2312.

https://doi.org/10.1182/blood.V118.21.2312.2312

Published: 2011

Journal Articles

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Bengt I. Eriksson, MD, PhD, Ola E. Dahl, MD,PhD, Cornelis N. van Dijk, MD,PhD, Simon P. Frostick, MA,DM,FRCS, Andreas A. Kurth, MD,PhD, Nadia Rosencher, MD, Janet Schnee, MD, Rohan Hettiarachchi, MD,PhD, Anita V. Christiansen, MSc.Pharm., Stefan Hantel, PhD, Harry R. Büller, MD,PhD

Blood (2006) 108 (11): 573.

https://doi.org/10.1182/blood.V108.11.573.573

Published: 2006

NARROW

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Email alerts

ASH Publications

American Society of Hematology

Dabigatran Etexilate or Warfarin in the Treatment of Acute Venous Thromboembolism in Western European Patients: A Pooled Analysis of RE-COVER ® and RE-COVER II™

Post-Hoc Analysis of RE-MEDY™ Demonstrates Significant Real-World Net Clinical Benefit for Dabigatran Versus Warfarin in Prevention of Secondary Venous Thromboembolism

Influence of Age and Renal Function on Efficacy and Safety of Dabigatran Versus Warfarin for the Treatment of Acute Venous Thromboembolism: A Pooled Analysis of RE-COVER™ and RE-COVER™ II

Evaluation of the Acute Coronary Syndrome Safety Profile of Dabigatran Etexilate in Patients Undergoing Major Orthopaedic Surgery: Findings From Four Phase III Trials

Oral Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip or Knee Arthroplasty: A Pooled Analysis of Four Randomized Trials

A New Oral Aniticoagulant, Dabigatran Etexilate, Is Effective and Safe in Preventing Venous Thromboembolism after Total Knee Replacement Surgery (The RE-MODEL Trial).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only